In the current work, using data from TCGA and the DFCI cohorts, it is shown that double mutant BRAF/PIK3CA colorectal cancers and BRAF mutant colorectal cancers without PIK3CA mutations, which represent 4.1% and 7.5% of cases in TCGA and 5.7% and 14.9% of cases in the DFCI cohort, respectively, differ in their clinical and genomic characteristics from the groups of patients without BRAF mutations. Here, BRAF is linked to colorectal cancer.